• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

The Valeant Saga Triggers Buying Opportunities in Biotech Stocks

Other companies have suffered following the debacle.
By BRET JENSEN
Mar 29, 2016 | 11:30 AM EDT
Stocks quotes in this article: VRX, MYL, TEVA, PRGO, AGN

This commentary originally appeared on Real Money Pro at 10:00 on March 29. Click here to learn about this dynamic market information service for active traders.

Valeant Pharmaceutical's (VRX) soap opera continued Monday. The stock fell another 7% to open the week, as its just-dispatched CEO was subpoenaed to testify before the Senate Special Committee on Aging on April 27. The committee is one of two investigating aggressive drug pricing, which has become a hornet's nest and a focus area in front of the upcoming election year. 

Valeant had already lost more market value from its peak than did Enron. The company has become a huge headache for hedge fund manager Bill Ackman, whose fund has a huge stake in this one-time market darling and has become its most ardent advocate. He recently took a board seat as well.

I have no stake in Valeant and I think you could make a case the stock price will be either $10.00 or $100.00 a year from now, depending on how all of its issues are resolved and what prices it can get for key assets, should it go down that route to shore up its balance sheet. 

Although this tragedy is fascinating to watch, I think the investment opportunities are in the selloffs in some of the large drug makers that this debacle has triggered, or at least play a key role in some significant declines.

This is especially true for two of the largest generic drug makers in the world, Mylan (MYL) and Teva Pharmaceuticals (TEVA). Teva actually tried to buy Mylan early in 2015 for over $80.00 a share, which Mylan successfully rebuffed, to the consternation of a good portion of their shareholder base.

Mylan was then in turn rejected by Perrigo Group (PRGO) before settling on taking over another European drug manufacturer named Meda for some $10 billion including debt. Although this acquisition triggered a nearly 20% pullback in the stock, the deal was accretive and got Mylan deeper penetration in some key markets outside of the United States.

Instead of buying Mylan, Teva ended up agreeing to buy the generics business of Allergan (AGN) for just over $40 billion, a deal that still is in the process of closing. Both firms are very diversified, have become cheap after dropping approximately 30% from their 52 week highs and have solid balance sheets.  Neither relies on price hikes, like Valeant did, as a core component of their business models.

Mylan should see earnings growth of 10% to 15% this year, and that growth should accelerate next year on the Meda acquisition, which has triggered an approximate $0.40 a share consensus earnings boost since it was announced. Mylan is extremely cheap at under 8x fiscal 2017's projected earnings per share.

2016 will be a transitional year for Teva, as it consolidates its huge purchase and earnings should only rise some 5% this year, which should accelerate to 10% growth in fiscal 2017. The company stated in the comments that accompanied its 2015 full year results that it believes it can achieve 20% average annual free cash flow growth from 2015-2018.

The stock is definitely in the bargain bin, selling at just 10x earnings, with a dividend yield of 2.5%.

Read more about the Valeant saga here:

  • Ousted Valeant CEO Subpoenaed by Congress
  • Valeant's $31 Billion Debt Could Be Fatal to Shareholders
  • Cramer Video: The Most Important Lesson From Valeant
  • Valeant vs. Sears: Will Bill Ackman Win This Time?
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Bret Jensen was long MYL, TEVA, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 03:07 PM EDT PAUL PRICE

    Why is Wal-Mart Down Big Today?

    Besides its poor earnings report Wal-Mart (WMT) wa...
  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login